Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,256 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
General Updates
Regulatory Filings Classification · 85% confidence The document is a short intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) 2015 to the stock exchanges, informing them of regulatory approval for a new drug indication. It does not present financial statements, governance details, or a report requiring publication—it is a routine regulatory compliance announcement. This falls under the generic “Regulatory Filings” category.
2026-05-21 English
Please find the enclosed intimation of the Company as per the captioned subject for reference.
Regulatory Filings Classification · 93% confidence The document is an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) 2015, notifying stock exchanges of regulatory approval for a new indication. It contains no financial statements or management commentary, nor is it an AGM, earnings, or annual report. It is a general regulatory disclosure, falling under the fallback category Regulatory Filings (RNS).
2026-05-21 English
General Updates
Regulatory Filings Classification · 85% confidence The document is an exchange filing under SEBI (Listing Obligations and Disclosure Requirements) Regulation 30(5) notifying the contact details of Key Managerial Personnel authorized to determine materiality. It does not present financial statements, results, or an actual report, nor does it announce a change in board or senior management. It is a routine regulatory disclosure, fitting the fallback category for miscellaneous regulatory announcements.
2026-05-20 English
Please find the enclosed intimation of the Company as per the captioned subject for your reference.
Regulatory Filings Classification · 87% confidence The document is a stock exchange filing by AstraZeneca providing contact details of Key Managerial Personnel as required under Regulation 30(5) of SEBI Listing Obligations and Disclosure Requirements. It is a compliance announcement rather than a substantive financial report or specific report itself. This falls under general regulatory filings/disclosures.
2026-05-20 English
Astrazeneca Pharma India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2026 ,inter alia, to consider and approve 1. The audited financial ....
Regulatory Filings Classification · 85% confidence The document is a compliance announcement to stock exchanges informing them of a forthcoming Board of Directors meeting date to consider approving audited financial results and recommending dividends. It contains no actual financial data or result figures and does not attach or publish any report itself. It does not propose management changes (MANG) or confirm dividend amounts (DIV), nor is it a report publication notice (RPA) because no report is being released. Therefore, it falls under the general regulatory announcements category (RNS).
2026-05-20 English
This is in reference to the intimation submitted to the exchange at 1:05 PM under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding ....
Declaration of Voting Results & Voting Rights Announcements Classification · 85% confidence The document is an official intimation under SEBI Listing Regulations informing stock exchanges that shareholders approved a special resolution (via postal ballot) shifting the registered office, with voting results declared on May 12, 2026. This is a declaration of voting results announcement rather than a full report or management change. Therefore it fits ‘Declaration of Voting Results & Voting Rights Announcements’ (DVA).
2026-05-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.